Gemcitabine and arabinosylcytosin pharmacogenomics: Genome-wide association and drug response biomarkers

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Li, Liang ^a   Fridley, Brooke L ^b   Kalari, Krishna ^b   Jenkins, Gregory ^b   Batzler, Anthony ^b   Weinshilboum, Richard M ^a   Wang, Liewei ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTARABINE; CYTIDINE DERIVATIVE; GEMCITABINE; MESSENGER RNA; SMALL INTERFERING RNA; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; HUMAN CELL; IC 50; LYMPHOBLASTOID CELL LINE; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; DNA MICROARRAY; ETHNIC GROUP; GENE LINKAGE DISEQUILIBRIUM; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; PHARMACOGENETICS;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CYTARABINE; DEOXYCYTIDINE; ETHNIC GROUPS; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INHIBITORY CONCENTRATION 50; LINKAGE DISEQUILIBRIUM; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER;

EID: 70450189297     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007765     Document Type: Article

References (63)

1. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, et al. (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409: 928-933.
2. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229.
3. Sabeti PC, Varilly P, Fry B, Lohmueller J, Hostetter E, et al. (2007) Genome-wide detection and characterization of positive selection in human populations. Nature 449: 913-918.
4. Altshuler D, Daly MJ, Lander ES (2008) Genetic mapping in human disease. Science 322: 881-888.
5. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, et al. (2004) Genetic analysis of genome-wide variation in human gene expression. Nature 430: 743-747.
6. Weidinger S, Gieger C, Rodriguez E, Baurecht H, Mempel M, et al. (2008) Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. PLoS Genet 4: e1000166.
7. Smid K, Bergman AM, Eijk PP, Veerman G, van Haperen VW, et al. (2006) Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids 25: 1001-1007.
8. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, et al. (2005) In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65: 9510-9516.
9. Gwee PC, Tang K, Sew PH, Lee EJ, Chong SS, et al. (2005) Strong linkage disequilibrium at the nucleotide analogue transporter ABCC5 gene locus. Pharmacogenet Genomics 15: 91-104.
10. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, et al. (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681.
11. Wu X, Gwyn K, Amos CI, Makan N, Hong WK, et al. (2001) The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. Carcinogenesis 22: 923-928.
12. Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, et al. (2000) Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. Aids 14: 2109-2116.
13. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, et al. (2006) Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 5: 853-867.
14. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, et al. (2007) Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 39: 1329-1337.
15. Gullans SR (2006) Connecting the dots using gene-expression profiles. N Engl J Med 355: 2042-2044.
16. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48: 4024-4031.
17. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, et al. (1992) Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52: 533-539.
18. Kern W, Estey EH (2006) High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 107: 116-124.
19. Kindler HL (2005) In focus: advanced pancreatic cancer. Clin Adv Hematol Oncol 3: 420-422.
20. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, et al. (2008) Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111: 4797-4808.
21. Bleibel WK, Duan S, Huang RS, Kistner EO, Shukla SJ, et al. (2009) Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet 125: 173-180.
22. Shukla SJ, Duan S, Badner JA, Wu X, Dolan ME (2008) Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics 18: 253-262.
23. Duan S, Bleibel WK, Huang RS, Shukla SJ, Wu X, et al. (2007) Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 67: 5425-5433.
24. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, et al. (2007) Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448: 470-473.
25. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, et al. (2008) Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 68: 7050-7058.
26. Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME (2008) Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 7: 3038-3046.
27. Li J, Burmeister M (2005) Genetical genomics: combining genetics with gene expression analysis. Hum Mol Genet 14 Spec No. 2: R163-169.
28. Bystrykh L, Weersing E, Dontje B, Sutton S, Pletcher MT, et al. (2005) Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'. Nat Genet 37: 225-232.
29. Schoch C, Haferlach T, Haase D, Fonatsch C, Loffler H, et al. (2001) Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 112: 118-126.
30. Seve P, Mackey JR, Isaac S, Tredan O, Souquet PJ, et al. (2005) cN-II expression predicts survival in patients receiving gemcitabine for advanced nonsmall cell lung cancer. Lung Cancer 49: 363-370.
31. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, et al. (2009) Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 325: 1246-1250.
32. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, et al. (2008) A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 13: 197-207.
33. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, et al. (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). 50:4417-22. Cancer Res 50: 4417-4422.
34. Lokiec F, Lansiaux A (2007) [Gemcitabine: from preclinic to clinic passing by pharmacokinetics]. Bull Cancer 94 Spec No Actualites: S85-89.
35. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, et al. (2006) Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab Pharmacokinet 21: 248-256.
36. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, et al. (2008) Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet 23: 379-384.
37. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, et al. (2006) Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 16: 429-438.
38. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, et al. (2005) Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11: 2620-2624.
39. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, et al. (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25: 32-42.
40. Hornstein I, Alcover A, Katzav S (2004) Vav proteins, masters of the world of cytoskeleton organization. Cell Signal 16: 1-11.
41. Trenkle T, McClelland M, Adlkofer K, Welsh J (2000) Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors. Gene 245: 139-149.
42. Turner M, Billadeau DD (2002) VAV proteins as signal integrators for multisubunit immune-recognition receptors. Nat Rev Immunol 2: 476-486.
43. Lagenaur C, Kunemund V, Fischer G, Fushiki S, Schachner M (1992) Monoclonal M6 antibody interferes with neurite extension of cultured neurons. J Neurobiol 23: 71-88.
44. Mukobata S, Hibino T, Sugiyama A, Urano Y, Inatomi A, et al. (2002) M6a acts as a nerve growth factor-gated Ca(2+) channel in neuronal differentiation. Biochem Biophys Res Commun 297: 722-728.
45. Alfonso J, Fernandez ME, Cooper B, Flugge G, Frasch AC (2005) The stress-regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine formation. Proc Natl Acad Sci U S A 102: 17196-17201.
46. Wu DF, Koch T, Liang YJ, Stumm R, Schulz S, et al. (2007) Membrane glycoprotein M6a interacts with the micro-opioid receptor and facilitates receptor endocytosis and recycling. J Biol Chem 282: 22239-22247.
47. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, et al. (2003) Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 278: 7607-7616.
48. Choy E, Yelensky R, Bonakdar S, Plenge RM, Saxena R, et al. (2009) Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet 4: 1-16.
49. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC (2002) Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 62: 1920-1926.
50. Feng WH, Hong G, Delecluse HJ, Kenney SC (2004) Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 78: 1893-1902.
51. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, et al. (2007) A genomewide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A 104: 9758-9763.
52. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
53. Wu Z, Irizarry R, Gentleman R, Martinez-Murillo F, Spencer F (2004) A model-based background adjustment for oligobucleotide expression arrays. J Am Stat Assn 99: 909-917.
54. Guo SW, Thompson EA (1992) Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48: 361-372.
55. Wigginton JE, Cutler DJ, Abecasis GR (2005) A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76: 887-893.
56. Schaid DJ, Batzler AJ, Jenkins GD, Hildebrandt MA (2006) Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata. Am J Hum Genet 79: 1071-1080.
57. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904-909.
58. Storey JD (2002) A direct approach to false discovery rates. J Royal Stat Soc B 64: 479-498.
59. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445.
60. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
61. Hauser MA, Li YJ, Takeuchi S, Walters R, Noureddine M, et al. (2003) Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum Mol Genet 12: 671-677.
62. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2008) Markov Model for Rapid Haplotyping and Genotype Imputation in Genome Wide Studies. University of Michigan.
63. Schadt EE (2005) Exploiting naturally occurring DNA variation and molecular profiling data to dissect disease and drug response traits. Curr Opin Biotechnol 16: 647-654.